Five-year real-world data on fingolimod treatment's effects on cognitive function

Abstract

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease that affects the central nervous system, resulting in physical, cognitive, and neuropsychiatric impairment (Langdon, 2011). Cognitive impairment (CI) is this disease's most frequent symptom, causing deficiencies in memory (long-term, episodic), information processing speed, complex attention, and executive functions, and has been detected in roughly one-third of patients with relapsing-remitting MS (pwRRMS) (Amato et al., 2010).